Embecta Corp. is a global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. The Company has a portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. It sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It also sells safety insulin syringes. It distributes its products through a variety of channels, including retail, hospitals and pharmacies.
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 1.08Bです。
高配当
同社は高配当銘柄であり、最新の配当性向は38.36%です。
割安
同社の最新のPEは1.64で、過去3年間の水準と比較して安値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は59.40M株で、前四半期比で7.24%減少しています。
HACAXが保有
スター投資家HACAXは本銘柄を1.28K株保有しています。
市場活動が活発
同社への投資家の関心が高まっており、20日間の売買回転率は3.59です。